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Abstract: Chronic obstructive pulmonary disease is a varied condition when examined from a 
number of different perspectives including factors which influence disease development, patho-
logical process and clinical features. There may be a complex interaction between the degree by 
which each of these processes influences the development of COPD and the subsequent clinical 
phenotype with which the patient presents. The varied host response and subsequent clinical 
phenotype has generated much interest in recent years. It is possible that failure of treatment 
to impact on mortality and reverse the disease process is because of the heterogeneous nature 
of the condition. Identification and targeted treatment of clinical and pathological phenotypes 
within the broad spectrum of COPD may therefore improve outcome. This article will review 
previous work which has attempted to phenotype COPD and identify if specific treatment for 
these phenotypes has been shown to be of benefit. It will examine the work on pathological 
processes and clinical manifestations, both pulmonary and systemic, and will focus on phar-
macological therapies.
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Introduction
Chronic obstructive pulmonary disease (COPD), as defined in recent guidelines, is 
“a preventable and treatable disease with some significant extra pulmonary effects that 
may contribute to the severity in individual patients. The airflow limitation is usually 
progressive and associated with an abnormal inflammatory response of the lung to 
noxious particles or gases.”1
The relationship between smoking and COPD is not absolute. COPD can occur 
in lifelong non-smokers;2 indeed more than 15% of subjects worldwide who die from 
COPD are non-smokers. Moreover, only approximately 30% of subjects who have a 
significant smoking history go on to develop clinically significant COPD.3
The host response to inhaled gases and particles appears to play an important role 
in development of COPD, and several factors have been identified which influence 
this process. Genetics,4 health in early life,5–7 nutrition,8 gender9 and socioeconomic 
status10 have all been shown to influence the development of COPD.
With so many factors influencing COPD it is unsurprising that it is a heterogeneous 
condition. Indeed the term Chronic Obstructive Pulmonary Disease was coined in the 
1970s to encompass what was previously recognized as three separate smoking-related 
lung diseases, chronic bronchitis, emphysema and chronic bronchiolitis. Each of these 
conditions is present to variable extents in individual patients. The systemic effects of 
COPD including skeletal muscle dysfunction,11 osteoporosis,12 cardiovascular disease,13 International Journal of COPD 2009:4 322
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weight loss14 and depression15 also vary within populations 
of COPD patients.
Our understanding of the pathogenesis of COPD has 
increased over the last 25 years. It is now apparent that a vari-
ety of pathological processes are involved in the development 
of COPD. Chronic inhalation of cigarette smoke presents 
a significant oxidant burden for the lungs. It has been sug-
gested that the ability of the lungs to cope with this oxidant 
burden has an important role in the pathogenesis of COPD.16 
Influx and activation of inflammatory leukocytes in the lungs 
is also a part of the inflammatory responses in the lungs in 
COPD. Increased numbers of neutrophils,17 macrophages,18 
eosinophils19 and t-cell lymphocytes20 have all been impli-
cated in the pathogenesis of COPD. The increased activity 
of inflammatory cells results in the release of an excess of 
proteolytic enzymes, such as neutrophil elastase (NE), in 
excess of antiproteases, such as α-1 antitrypsin (AAT). This 
protease/antiprotease imbalance may result in lung tissue 
damage and subsequent development of COPD.21
In addition to imbalances between proteases/antiproteases 
and oxidants/antioxidants, mechanisms related to enhanced 
inflammatory responses include enhanced epigenetic 
mechanisms and autoimmunity.22,23
In parallel with an improved understanding of the 
pathogenesis of COPD, treatment for COPD has significantly 
advanced in the last 25 years. Short-acting bronchodilators 
can improve health status and symptomatic control but not 
mortality.24–27 Long acting bronchodilators have also been 
shown to improve symptoms, exercise capacity and exacer-
bation rates.28,29 Tiotropium, a long-acting anticholinergic, 
has been shown to reduce exacerbation rates, improve quality 
of life and increase forced expiratory volume in one second 
(FEV1) in stable COPD.30 There is no published data as yet 
supporting a long-term survival benefit from tiotropium. 
A recent publication suggests that treatment with inhaled 
corticosteroid and long-acting β agonist therapy has survival 
benefit compared to tiotropium alone.31
Inhaled corticosteroids (ICS) also have a role in COPD 
and can improve health status and reduce exacerbation 
rates.32,33 Inhaled corticosteroid therapy in combination 
with long-acting β agonist (LABA) have been shown to be 
of greater benefit that ICS alone.34,35 Treatment with ICS is 
currently recommended for subjects with an FEV1 less than 
50% who have more than one exacerbation per year,36 but this 
guideline may have to be revised in the light of recent large 
clinical trials showing the benefit of combinations of ICS and 
long-acting β agonists on symptom control, exacerbation rates 
and the rate of decline in airways obstruction.37,38
However, with the exception of one randomized 
controlled trial of ICS/LABA,37 none of these treatments are 
able to improve life expectancy or reverse the COPD process. 
Furthermore none of these therapeutic trials take into account 
the heterogeneous nature of the condition.
Long term oxygen therapy in subjects with signifi-
cant respiratory failure and can improve mortality and 
morbidity.39,40 There is also evidence that pulmonary rehabili-
tation improves mortality and morbidity in selected patients 
with COPD.41
As described above, Chronic Obstructive Pulmonary 
Disease is a varied condition when examined from a number 
of different perspectives including factors which influence 
disease development, pathological process and clinical fea-
tures. There may be a complex interaction between the degree 
by which each of these processes influence the development 
of COPD and the subsequent clinical phenotype with which 
the patient presents. The varied host response and subsequent 
clinical phenotype has generated much interest in recent 
years. It is possible that failure of treatment to impact on 
mortality and reverse the disease process is because of the 
heterogeneous nature of the condition. Identification and 
targeted treatment of clinical and pathological phenotypes 
within the broad spectrum of COPD may therefore improve 
outcome.
This article will review previous work which has 
attempted to phenotype COPD and identify if specific treat-
ment for these phenotypes has been shown to be of benefit. 
It will examine the work on pathological processes and 
clinical manifestations, both pulmonary and systemic and 
will focus on pharmacological therapies.
Oxidative stress in COPD
Oxidative stress results from an imbalance between oxidants 
and antioxidants in favor of oxidants.42 This can occur from 
either an increase in oxidant burden or a decrease in anti-
oxidant or both. An increase in oxidant burden in the lungs 
can result from inhalation of oxidants, such as those derived 
from cigarette smoke or air pollution, or as a result of the 
influx of inflammatory leucocytes which are activated to 
release reactive oxygen species. Inhalation of toxic particles 
and gases in cigarette smoke and the subsequent oxidative 
stress can cause direct damage to lipids and proteins in the 
lungs.43,44 Molecular pathways and signalling mechanisms are 
stimulated by oxidative stress45 resulting in increased gene 
expression, production of pro-inflammatory cytokines,46,47 
influx of inflammatory leukocytes and subsequent enhanced 
inflammation in the lung.48International Journal of COPD 2009:4 323
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Most of the antioxidant capacity of the lung is extra-cellular, 
present in the airspace epithelial lining fluid (ELF).49 The 
most important antioxidant in the epithelial lining fluid is 
glutathione. This compound has poor bioavailability when 
given by mouth limiting its use as a disease modifying 
agent. N-acetylcysteine (NAC), a precursor of glutathione, 
is biochemically active in humans. In vitro NAC treatment 
of fetal membranes results in a reduction in production of 
pro-inflammatory cytokines.50 In animal models, oral NAC 
inhibits lung inflammation51 and attenuates elastase induced 
emphysema.52
Treating oxidative stress
NAC has been shown to increase glutathione levels in 
human populations, both healthy subjects53 and those with 
COPD.54 Oral NAC results in increased plasma glutathione 
in COPD, but does not appear to influence bronchoalveolar 
lavage (BAL) levels of glutathione in patients with COPD.54 
However the proportion of lymphocytes in BAL decreased 
to levels comparable to non smoking controls after treatment 
with oral NAC.55
Low dose NAC (600 mg od) in patients with COPD 
over a 12-month placebo controlled trial reduced levels 
of hydrogen peroxide in exhaled breath condensate after 
9 and 12 months, but not after 6 months of treatment.56 
Gerrits et al performed a retrospective analysis studying 
the impact of the introduction of NAC at high doses at the 
first hospital presentation with an exacerbation of COPD. 
This analysis suggested that NAC reduced the risk of read-
mission by 33% after adjustment for disease severity.57 
However, a further retrospective analysis suggested that oral 
NAC does not appear to impact on time to recover from an 
exacerbation.58
A Cochrane database review of randomized, double 
blind, placebo controlled studies with a variety of oral 
mucolytics, including n acetyl cysteine, was performed 
in subjects with chronic bronchitis (21 studies) or COPD 
(2 studies). Trials included in the review were to be 
of at least two months duration. This demonstrated a 
reduction in exacerbations of COPD compared with 
placebo. Six trial subjects required treatment with an oral 
mucolytic to prevent one exacerbation in the study period 
(range 2 months to 24 months) compared with placebo.59 
A quantitative systematic literature review of the use of 
NAC specifically has also been carried out. This review 
identified 11 randomized placebo controlled trials of 
NAC, daily doses between 400 mg and 600 mg, in treat-
ment of chronic bronchitis over periods between 12 and 
24 months. Nine of the 11 papers used exacerbation rate 
as an end point. Overall a reduction in exacerbations was 
identified in NAC versus placebo (30%–60% vs 40%–81%), 
with 5.8 patients requiring treatment for trial duration to 
prevent one exacerbation. An improvement in symptoms 
of breathlessness was also noted in the 5 trials which used 
this as an endpoint, 61.4% demonstrating an improvement 
in breathlessness in NAC versus 34.6% in placebo.60
The majority of studies discussed above were retrospective. 
A recent large scale prospective multicenter, double blind 
placebo control study, the Bronchus trial, of 600 mg OD 
of NAC over 3 years versus placebo was performed in 
523 patients. No effect was noted on exacerbation rates or 
rate of decline in FEV1. Subgroup analysis of steroid naïve 
patients demonstrated a relative risk reduction for exac-
erbation of 0.79; however no effect was demonstrated on 
spirometry in this group.61
In conclusion oral NAC appears to play a role in the 
management of subjects with chronic bronchitis. This 
is most likely due to increasing intracellular glutathione 
although the chemical itself may also have direct antioxidant 
effect along with mucolytic properties. Alternatively the 
mucolytic property of NAC may be more likely to be of 
benefit in subjects with mucus hypersecretion. However, 
when this treatment is extended to the whole spectrum of 
COPD the results are less encouraging, possibly because 
oxidative stress is less important in development of other 
phenotypes. Targeting NAC treatment in subjects with the 
chronic bronchitis phenotype of COPD may help to reduce 
exacerbations.
Lung inflammation in COPD
Oxidative stress in the lungs results in increased gene 
expression and production of pro-inflammatory cytokines.62 
This in turn causes both influx and activation of inflam-
matory leukocytes. Increased numbers of neutrophils, 
macrophages, eosinophils and T lymphocytes have all been 
associated with the development of COPD. Induced sputum 
neutrophil differentials are higher in smokers with airflow 
limitation, when compared with smokers with normal 
lung function.17, 63,64 There is also evidence that the percentage 
of neutrophils in induced sputum correlates with the rate of 
decline of FEV1 in COPD.65 Higher levels of neutrophils are 
also seen in the small airways and lung parenchyma in COPD, 
although this is not as marked as in the larger airways.66 
Neutrophils are thought to play an important role in the 
pathogenesis of COPD releasing elastase, metalloproteases 
and free radicals.67International Journal of COPD 2009:4 324
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The pro-inflammatory cytokine interleukin 8 (IL-8) 
is a potent chemotaxin for neutrophils and plays a role 
in recruitment and activation of neutrophil and alveolar 
macrophages.68 Neutrophil cellular influx may result in 
endothelial injury which increases neutrophil- endothelial 
cell adhesion.69
Although the association between neutrophils and the 
pathogenesis of COPD is the most frequently studied, 
other inflammatory cell types have been implicated in the 
development of COPD. Patients with COPD appear to have 
higher levels of macrophages; a twenty five fold increase in 
macrophage numbers is seen in resected lung from COPD 
patients compared with normal smokers.18,70 Furthermore, 
alveolar macrophages in patients with COPD are more 
active, secreting higher numbers of inflammatory proteins 
and demonstrating higher elastolytic activity compared with 
normal smokers.71 There is also an association between 
macrophage numbers and COPD severity.64 Macrophages in 
COPD patients have greater elastolytic activity. The major 
elastolytic enzyme secreted by AM in patients with COPD is 
matrix metalloproteinase 9 (MMP-9), whose activity is regu-
lated by the transcription factor Nuclear Factor κB (NF κB), 
whose activation is associated with the development of 
COPD.72,73
Together with neutrophils and macrophages, both 
eosinophils and t-cell lymphocytes have been shown to be 
associated with the development of COPD. Eosinophils are 
elevated in airway wall biopsies of patients with COPD.20 
There is also increased production of eosinophilic cationic 
proteins in BAL of patients with COPD.74 Increased t-cell 
lymphocytes have also been demonstrated in airways 
and lung tissue of patients with COPD. These T-cells are 
predominantly CD8 positive, which may contribute to 
parenchymal destruction.75
Eosinophilic bronchitis, defined as greater than 3% eosin-
ophils in sputum, is predominately associated with asthma. 
Subjects with eosinophilic bronchitis may go on to develop 
chronic airflow obstruction without a significant smoking 
history.76 It is not uncommon to find subjects with COPD 
with high levels of eosinophils in their sputum.77 Rutgers et al 
found higher levels of eosinophils in the induced sputum and 
BAL fluid of non smoking COPD subjects compared to non 
smoking controls.78 Furthermore, Lams et al found increased 
levels of activated eosinophils in the submucosa of resected 
lungs in smokers with COPD and current smokers compared 
to non smoking controls.79
Brightling et al gave 2 weeks of prednisolone (30 mg/day) 
or placebo to 67 patients with COPD in a double blind control 
trial. They found that prednisolone significantly reduced the 
levels of eosinophils in induced sputum. Those subjects with 
high levels of eosinophils (4.5%) demonstrated significant 
improvement in exercise capacity and FEV1.80 Smokers 
with any form of airways disease, including COPD, and 
eosinophilic bronchitis have increased levels of reversibility 
compared to subjects with lower levels of eosinophils in 
sputum.81 These data suggest that identification and treatment 
of eosinophilic bronchitis in COPD may be of benefit in a 
selected patient group.
Anti-inflammatory therapy in COPD
Despite increasing evidence that pulmonary inflammation 
is a major factor in development of COPD, there is little 
evidence as yet that treatment of this inflammation, other 
than with inhaled corticosteroids, is of benefit.
Tumour necrosis factor alpha is a pro-inflammatory 
cytokine associated with inflammatory cell recruitment in the 
lung and the subsequent development of COPD.82 TNF-α has 
been shown to stimulate inducible nitric oxide synthase in 
human vascular endothelium resulting in increased nitrosai-
tive stress.83 Hypoxic alveolar macrophages have been shown 
to release TNFα which in turn results in oxidative stress by 
activating NF κB,84 furthermore transactivation of NF-κB 
by reactive oxygen species in cell models is synergized by 
TNFα.85,86 TNF-α is also a neutrophil chemotaxtic agent82 
and elevated in sputum supernatant in COPD.87
Plasma levels of TNFα are elevated in COPD subjects 
with a low body mass index (BMI) compared with those with 
a normal BMI and also healthy controls.88
TNF-α blockade has been developed as a therapy for con-
nective tissue diseases such as rheumatoid arthritis. A double 
blind placebo controlled study of TNF-α blockade in COPD, 
using the drug infliximab, has recently been published. Two 
hundred and thirty-four patients with moderate to severe 
COPD were given either infliximab, at either 3 mg/kg or 
5 mg/kg or placebo. This study failed to demonstrate any 
impact on health status, FEV1, 6 minute walk distance or 
exacerbation rate. Furthermore, a non statistically significant 
increase in frequency of malignancy in treatment group was 
seen.89 It may be that a specific phenotype of the COPD 
population may respond to TNF-α blockade.
A study of 30 patients with severe COPD divided into 
emphysematous and chronic bronchitis clinical phenotypes 
found that subjects with clinical emphysema had higher levels 
of TNF-α in serum and lower fat free mass.90 COPD patients 
with evidence of low muscle mass, as measured by BMI and 
creatinine height index, had higher levels of TNF-α in serum International Journal of COPD 2009:4 325
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compared to COPD patients with normal muscle mass.91 
Selection of subjects with evidence of elevated TNF-α levels 
may therefore demonstrate benefit.
A further potential anti-inflammatory therapy is phospho-
diesterase 4 (PDE4) inhibitors, which result in an increase in 
intracellular cyclic adenosine monophosphate. This action 
has anti-inflammatory properties including reduced produc-
tion of pro-inflammatory cytokines92 and recruitment of 
inflammatory leukocytes.93 Phosphodiesterase 4 inhibition 
has also been shown to decrease TNF-α levels in bronchial 
epithelial cells94 and reduce matrix metalloproteinase-9, 
a proteolytic enzyme, activity.95
Clinical studies of the efficacy of cliomast and roflumilast, 
two selective phosphodiesterase-4 inhibitors, in COPD have 
been in published. A Cochrane database review of cliomast 
in COPD (4 trials) demonstrated small increases in FEV1 
and reduced exacerbation rates when compared to placebo.96 
Rabe et al showed that roflumilast treatment for 24 weeks 
in 1411 patients increased FEV1 compared to placebo and 
reduced exacerbation rate from 1.13/per year in the placebo 
group to 1.03/year at low dose (250 µg) and 0.75 per year at 
high dose (500 µg).97 A statistically significant improvement 
on FEV1, but not exacerbation rate, was sustained after 1 
year of treatment.98 These studies did not specifically target 
COPD patients with evidence of high levels of pulmonary 
inflammation. Several side effects are however associated 
with PDE4 inhibitors, including nausea and vomiting which 
affect the tolerability of these drugs. However the newer 
generation drugs of this class appear to be better tolerated.
Other potential anti-inflammatory therapies are as yet 
unproven. Previous studies of inhibition of IL-8 using a 
monoclonal antibody were of limited benefit, with improved 
dyspnea scores but no impact on FEV1, health status 
or 6 minute walk99 and further development seems unlikely.100 
Reduction of inflammation by granulocyte macrophage 
colony stimulating factor may potentially be of benefit but 
there are as yet no clinical studies.101
Protease antiprotease imbalance
Chronic increased levels of pro-inflammatory cytokines 
and inflammatory leukocytes have been associated with 
the development of COPD Inflammatory leucocytes cells 
release proteolytic enzymes such as neutrophil elastase (NE), 
in excess of antiproteases, such as AAT. Other proteolytic 
imbalance may also occur between matrix metalloproteases 
and their inhibitors. This protease/antiprotease imbalance 
results in lung tissue damage and subsequent development 
of COPD.71
Excess production of neutrophil elastase results in 
degradation of elastin, proteolysis and glycoproteins along 
with abnormalities in surfactant production.21 NE also 
induces expression of the cytokine IL-8 in airway epithelial 
cells.102 Tracheal instillation of NE in guinea pigs induces 
emphysema.103 Furthermore NE inhibition reduces cigarette 
smoke induced emphysema in guinea pigs.104 Other proteases 
are also involved. MMP-9 is the predominant elastolytic 
enzyme released by macrophages in COPD and is regulated 
by the NFκB pathway.73 Other molecules with proteolytic 
activity include cathepsin G and proteinase 3. The lysomal 
cysteine proteases may also play a role in COPD.105
In parallel with an excess of proteases, development of 
COPD is associated with inactivation or insufficiency of 
antiproteases. AAT is the main antiprotease in lung paren-
chyma. Subjects with AAT deficiency develop emphysema 
early.106 Alpha-1 antitrypsin (ATT) deficiency is probably the 
best characterized phenotype of COPD. Impaired production 
of this proteinase results in early development of emphysema 
in smokers. There is a genetic association with ATT, the 
genotype protease inhibitor (PI) ZZ being most commonly 
associated with disease. The incidence of this genotype was 
1 in 6000 in a Swedish study of 200 000 newborns.107 The 
PIZZ genotype is seen in between 1 and 4.5% of subjects with 
COPD.108 There are several other genotypes associated with 
ATT deficiency including MZ, MS, SS and SZ.109
Together with absolute or relative deficiency, inactivation 
of AAT has been identified in COPD. Oxidative stress 
through cigarette smoke, perioxynitrite and chemically 
generated oxidants have been shown to inactivate antipro-
teases in vitro.110,111 Other antiproteases, such as secretory 
leukoprotease-1 (SLP-1), are present in the airways and may 
also be inactivated by oxidative stress.112
Treating protease/antiprotease 
imbalance
Treating the excessive protease activity in COPD may 
improve outcome, specifically in patients where this plays a 
significant pathogenic role. Protease/antiprotease imbalance 
is the major defect in ATT deficiency therefore antiprotease 
therapy is most commonly studied in this phenotype of 
COPD although there are some studies of this treatment in 
the emphysematous phenotype.
Prolastin is an antiprotease which can be purified 
from the plasma of healthy donors and then administered 
intravenously to subjects with ATT deficiency. Augmentation 
therapy has been shown to increase the levels of ATT in 
plasma113 and epithelial lining fluid114 along with reducing International Journal of COPD 2009:4 326
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bronchial inflammation.115 There is limited evidence for the 
benefit of this therapy with no randomized control trial data,116 
however the treatment appears to be well tolerated.117 The 
current American Thoracic Society/European Respiratory 
Society guidelines for management of AAT deficiency 
suggest consideration in those subjects with FEV  1 between 
35% and 65% predicted.108
Another potential therapy targeted at repairing the 
emphysematous COPD phenotype is all-trans-retinoic acid 
which has been shown to reverse emphysema in rats,118 
although not in adult mice.119 This has led to a number of 
trials of the role of all-trans-retinoic acid in ATT deficiency. 
An initial study of 20 patients showed that this therapy was 
well tolerated, but there was no change in lung function or CT 
appearance after 3 months,120 larger and longer term studies 
are awaited. A recent publication, the FORTE study, studied 
the role of retinoids in emphysema not associated with ATT 
deficiency. One hundred and forty-eight subjects with COPD 
who had impaired diffusion capacity and low CT density 
were treated with all-trans-retinoic acid for 6 months in a 
double-blind placebo-controlled trial with either 1 mg/kg/day 
or 2 mg/kg/day of retinoic acid.121 Overall, results were 
disappointing with no impact on CT appearance or lung 
function. Post hoc analysis did suggest that those subjects in 
the group receiving the higher dose who were able to achieve 
high plasma levels had some improvement in emphysema as 
assessed by CT scanning, health status and gas transfer for 
carbon monoxide.121
Another potential treatment targeted at the proposed 
protease/antiprotease imbalance in COPD is the drug 
hyaluronan, which has been shown to prevent elastic fibre 
elastolysis, resulting from the effects of neutrophil elastase 
and human metalloproteinases.122 Hyaluronan may also 
improve hydration of elastic fibres, preventing elastic tissue 
damage.123 There are ongoing clinical trials of this therapy, 
but as yet there is no evidence of benefit.124
Pathological phenotypes in COPD
The FORTE study, mentioned above, is an example of patient 
selection for treatment within the COPD population based 
on clinical phenotype. There have been several recent pub-
lications on clinical phenotypes in COPD. A recent study by 
Patel et al125 suggested that there were significant differences 
in the processes involved in the development of parenchymal 
and airways disease in COPD. Development of emphysema 
appeared to have stronger genetic links, with siblings of 
subjects with emphysema more likely to have emphy-
sema themselves without a strong relationship between 
levels of emphysema and smoking pack years. A stronger 
relationship was noted between FEV1 and pack years in non 
emphysematous COPD, compared to emphysematous COPD 
subjects.125 Subjects with severe emphysema on CT scan are 
more likely to have lower BMI and worse health status com-
pared to subjects with mild or no emphysema independent 
of FEV1.126 A study by Fujimoto et al divided 172 patients 
with COPD into three groups on the basis of the presence 
or absence of emphysema and bronchial wall thickening. 
Those with emphysema but no bronchial wall thickening 
had lower BMI, lower gas transfer and reduced reversibility 
compared to those with bronchial wall thickening, but no 
emphysema.127 A smaller study, of 24 patients, demonstrated 
increased inflammatory leukocytes in the sputum of subjects 
with evidence of emphysema on CT scan compared to those 
without emphysema.128
Two major smoking related forms of emphysema are 
recognized, centriacinar and panacinar. Centriacinar, also 
known as centrilobular, relates to damage of alveoli around 
the respiratory bronchioles and the central portions of 
the acinus. Centriacinar damage is usually most marked 
in the upper lobes. Panacinar emphysema, associated 
with uniform damage of airspaces distal to the terminal 
bronchioles, is linked with α1 antitrypsin deficiency and 
predominately affects the lower lobes.19 There is some 
speculation in the literature that these two processes have 
different pathological origins, with centriacinar related to 
airways damage and inflammation and panacinar a result 
of impaired anti-inflammatory response to inhaled insults 
such as cigarette smoke.129,130 Previous work in this field 
has been based on pathological specimens. Improved lung 
imaging techniques allow less invasive differentiation 
of the emphysematous phenotype.131 This may facilitate 
increased research of the underlying pathological process 
involved.
As described above there is increasing evidence that 
different inflammatory pathways involved in COPD 
pathogenesis may affect the clinical phenotype of COPD 
which develops. There is, as yet, limited proof that 
pharmacological targeting of pathways specific to the indi-
vidual will have any impact on morbidity and mortality.
Targeting pathological phenotypes 
in COPD
The National Emphysema Treatment Trial (NETT) is a good 
example of targeted therapy in COPD. Lung volume reduc-
tion surgery (LVRS) for treatment of emphysema having 
previously been described in the 1950s was reintroduced International Journal of COPD 2009:4 327
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in 1990s. Initial reports were encouraging from specialist 
centers with improved FEV1 and PaO2.132 However as LVRS 
became more widely used clinical improvements were 
less apparent and 90 day mortality was higher than in the 
initial publications.133 This led to the development of the 
National Emphysema Treatment Trial. In this study over 
1200 patients were randomized to either medical therapy 
or lung volume reduction surgery and followed up over a 
five year period. Exacerbation rates were reduced in the 
surgical arm by 30% compared to medical therapy and time 
to first exacerbation was also reduced.134 However, there 
was no impact on morbidity and health status. Post hoc 
analysis of the NETT trial has identified a specific cohort 
who derives most benefit from this treatment. Subjects 
with low exercise capacity and predominant upper lobe 
emphysema have significant improvement in quality of 
life.135 Furthermore, LVRS in these individuals may impact 
on survival.136 This study suggests that rigorous patient 
selection, matching the treatment to the individual may 
help improve outcomes in COPD.
Pulmonary and systemic 
manifestations of COPD
The second part of this review will describe some pulmonary 
and systemic manifestations of COPD and discuss if 
identification and treatment of these conditions may improve 
outcome.
Pulmonary artery hypertension  
in COPD
Pulmonary artery hypertension (PAH) is associated with 
COPD. The incidence of significant PAH in COPD is 
estimated at around 1 to 2/1000.137 This increases in 
severe disease. Right heart catheterization data from the 
National Emphysema Treatment Trial showed that out of 
120 subjects with severe emphysema the mean pulmonary 
artery pressure (PAP) was 26 mmHg with approximately 
25% having a resting PAP greater than 30 mmHg. Further-
more, in a study of 131 COPD subjects who had normal 
resting PAP, 76 demonstrated evidence of exercise induced 
PAH. Thirty-three of the 131 went on to demonstrate 
resting PAH after between 5 and 6 years follow up.138 
Raised PAP in COPD has a negative impact on survival139 
and is associated with poor response to long-term oxygen 
therapy (LTOT).140
Whilst PAH in COPD is thought mainly to be due 
to hypoxia, pulmonary vascular remodelling has been 
shown to affect all layers of the pulmonary vessel walls 
in COPD.141 As such reversal of hypoxia alone will not result 
in improvement in pulmonary hypertension,142 which was 
confirmed in the Nocturnal Oxygen Treatment Trial.39 Other 
factors which may influence the development of PAH in 
COPD include cigarette smoking, which may have an impact 
on pulmonary vessels,143 and pulmonary inflammation.144
Over the last 10 years new therapies, such as endothelin 
receptor antagonists145 and phosphodiesterase inhibitors,146 
have become available for idiopathic PAH (iPAH). These 
treatments are more easily administered and better tolerated 
than previous therapies, such as intravenous prostacyclin, and 
have been shown to improve exercise capacity, quality of life 
and survival in iPAH. However as yet there is little published 
data of the effect of these new agents in PAH associated 
with COPD. The incidence of significant PAH in COPD is 
estimated to be 100 fold that of iPAH therefore investigated 
and treating this condition would have significant cost 
implications.147
Recurrent exacerbations of COPD
Bacterial colonization in COPD is associated with declining 
FEV1. Increased bacterial load is associated with increased 
rate of decline in FEV1.148 Subjects with severe COPD 
have increased frequency of exacerbations of COPD 
compared with milder forms of the disease.149 Banerjee 
et al studied 67 subjects with stable COPD for evidence 
of potentially pathogenic organisms (PPO) in induced 
sputum. Those subjects with PPO have higher levels of 
airways inflammation and worse health status, compared 
to those without pathogenic organisms independent of 
FEV1, age and BMI.150 A similar study using bronchoal-
veolar lavage (BAL) demonstrated that in COPD subjects 
bacterial colonization is associated with higher levels of 
inflammation in BAL.151
COPD subjects who experience frequent exacerbations 
are more likely to have bacterial colonization, compared with 
infrequent exacerbators.152
Eradication of bacterial pathogens after an exacerbation of 
COPD is associated with reduced levels of bacterial coloniza-
tion and bronchial inflammation.153 There is however no study 
demonstrating the long-term impact of eradication of poten-
tial pathogenic organisms from the bronchial tract. There 
is evidence that chronic use of Azithromycin, a macrolide 
antibiotic, in cystic fibrosis improves FEV1 and may also 
reduce exacerbations and improve quality of life154 and there 
is an ongoing study of its impact in COPD.
Identification and treatment of bacterial colonization 
and pulmonary hypertension may be of benefit in COPD, International Journal of COPD 2009:4 328
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although there is limited evidence for this as yet. In a similar 
way, identifying and managing the systemic effects of COPD 
may improve outcomes and is discussed below.
Systemic inflammation in COPD
COPD is associated with high levels of systemic inflam-
mation, probably secondary to pulmonary inflammation.155 
This systemic inflammation has been shown to affect the 
cardiovascular system, muscle mass and bone metabolism. 
All of these factors are discussed below, as well as the affect 
of COPD on mental health.
Man et al published a study of 4803 patients with mild 
to moderate COPD. This demonstrated that high levels of 
systemic inflammation, as measured by serum C reactive 
protein (CRP), were associated with increased all cause 
mortality, cancer and cardiovascular death.155
Cardiovascular risk in COPD
There is increasing evidence that COPD is associated with 
cardiovascular risk. Zureik et al studied 194 subjects with 
COPD and measured arterial stiffness as an assessment of 
cardiovascular disease. They found that as FEV1 fell there 
was an increase in the degree of arterial wall stiffness, indicat-
ing that airflow obstruction may be an independent risk factor 
for cardiovascular disease.156 Sin and Man demonstrated that 
subjects with severe airflow obstruction are more likely to 
have electrocardiogram evidence of ischemic heart disease 
compared to subjects with no airflow obstruction. One 
possible explanation for this is that systemic inflammation 
as a result of COPD results in systemic vascular endothe-
lial damage. In support of this hypothesis, higher levels of 
systemic inflammation were found in those COPD subjects 
with evidence of ischemic heart disease.157
There is evidence of benefit in treating cardiovascular 
disease in COPD, both in terms of cardiovascular 
and respiratory outcomes. Soyseth et al performed a 
retrospective analysis on 854 subjects admitted to hos-
pital with an exacerbation of COPD. They found that 
subjects treated with statins had a hazard ratio for death 
of 0.57 compared to subjects not taking this treatment. 
Survival was further improved in the group taking inhaled 
corticosteroid with a statin with a hazard ratio of 0.39 com-
pared to the cohort not on either an inhaled corticosteroid 
or a statin.158
A further retrospective analysis of almost 6000 patients 
with COPD by Mancini et al found that use of a statin 
in combination with either an angiotensin converting 
enzyme inhibitor or an angiotensin II receptor blocker had 
a significant impact on both cardiovascular and respiratory 
disease.159 These therapies were associated with reduced 
frequency of hospital admission from exacerbation of COPD, 
reduced incidence of myocardial infarction and reduced 
overall mortality.
Identification and treatment of cardiovascular disease in 
COPD, possibly as a result of systemic inflammation, may 
improve mortality and morbidity in this population. However 
there has not as yet been any double-blind placebo-controlled 
trial to support this hypothesis. Furthermore a recent logistical 
regression analysis of cardiovascular risk in relation to lung 
function suggested that the increased cardiovascular disease 
in COPD may relate to traditional risk factors. This study 
found that after correcting for age, sex, smoking history, 
hypertension, cholesterol and diabetes, the risk of cardiac 
disease associated with airflow obstruction was significantly 
reduced.160
Nutrition in COPD
A further aspect of the systemic effects of COPD is adverse 
nutritional effects and low body mass. Several studies have 
demonstrated an association between poor nutrition and 
COPD. Low fresh fruit intake is associated with lower FEV1
8 
and development of airflow limitation is associated with 
reduced dietary vitamin C intake161,162 whilst high intake of 
fruit and whole grains appears to protect against declining 
lung function.8 Weight loss or a low BMI is associated with 
increased COPD mortality, this relationship being stron-
gest in severe COPD.14,163,164 Therefore targeting COPD 
patients with low BMI and offering nutritional support may 
improve outcomes. However studies to date have not been 
encouraging.
A meta-analysis published in 2000 identified 9 random-
ized controlled trials of nutritional supplementation in 
COPD. These studies did not demonstrate any significant 
impact from supplementation with no improvement in 
lung function or exercise capacity,165 although this may in 
part relate to the severity population studied.166 Creatinine 
supplementation in a randomized control trial (RCT) of 38 
patients improved health status and fat free mass but not 
exercise capacity.167
A more recent RCT trial showed that nutritional 
supplementation resulted in improved exercise capacity in 
well nourished, but not undernourished, patients.168 One 
possible explanation for the rather poor results in this trial 
is that the subgroup of patients who have relative anorexia 
and high levels of inflammation are least likely to respond 
to nutritional supplementation.169 Treating the inflammation International Journal of COPD 2009:4 329
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which causes low BMI in these subjects may be more 
important than treating the outcome. However this hypothesis 
requires testing.
A specific aspect of COPD associated with poor nutrition 
is muscle wasting. Schols et al reported in 1993 that 49% 
of patients attending for pulmonary rehabilitation had 
evidence of reduced muscle mass.170 Subjects with reduced 
muscle mass have reduced exercise capacity and poorer 
health-related quality of life.171
Several factors present in COPD impact on the loss of 
skeletal muscle including hypoxia,172 the use of oral and 
inhaled glucocorticoids,173 systemic inflammation174 and 
oxidative stress.175 Local inflammation may be reduced in 
the muscles of subjects with COPD compared to controls 
although the implication of this finding is not yet fully 
understood.176
Pulmonary rehabilitation has been shown to improve 
exercise capacity and health status in COPD.177 Creatine 
supplementation in subjects undertaking pulmonary 
rehabilitation programmes has been shown to further improve 
quality of life, but not exercise capacity.167 As yet there are 
no studies which demonstrate improved mortality associated 
with increasing muscle mass in COPD and there appears to be 
limited evidence of the benefit of nutritional supplementation 
alone in patients with reduced skeletal muscle mass.
Osteoporosis in COPD
A further disease associated with the systemic effects of 
COPD is osteoporosis.178 Cigarette smoking is an inde-
pendent risk factor for osteoporosis in healthy subjects.179 
McEvoy et al demonstrated in 1998 a high incidence of 
vertebral fractures in subjects with COPD (50%) compared 
to controls. Furthermore, COPD subjects on regular gluco-
corticoid had increased risk of vertebral fracture compared 
to steroid naïve subjects with an odds ratio of 1.38 for ICS 
and 2.16 for oral.180
Together with increased glucocorticoid use, several other 
factors have been identified which influence osteoporosis 
development. A recent study of osteoporosis in COPD 
demonstrated high incidence of low bone density, with a 
significant relationship between bone mineral density and 
disease severity as assessed by GOLD stage. Subjects from 
GOLD stage IV had a 7.6-fold increase risk of low bone 
mineral density compared to GOLD stage II. Low BMI was 
also a predictor of low bone mineral density.181
The reduced mobility and muscle strength associated 
with COPD is also a risk for development of osteoporosis.12 
Subjects with COPD have lower levels of vitamin D, 
crucial for bone development.182 The increased systemic 
inflammation in some subjects with COPD may also play 
a role.178 Along with the direct impact of osteoporosis on 
morbidity and mortality, the kyphosis associated with 
vertebral fracture can have a negative impact on lung 
function.183 These studies would suggest that subjects with 
high corticosteroid use, low BMI and high levels of inflam-
mation are at risk of osteoporosis and targeted intervention 
may be of benefit.
A recent review by Gluck and Colice184 recommended 
assessment for osteoporosis in both males and females 
with COPD aged greater than 60 with a significant smok-
ing history. However to date there is limited information 
about the benefits of intervention specifically in COPD. 
Risedronate has been shown to both reduce the risk of 
vertebral fracture in glucocorticoid induced osteoporosis185 
and maintain bone mineral density (BMD) with steroid 
treatment.186 Alendronate also prevents glucocorticoid 
induced osteoporosis.187 These studies included all disease 
processes requiring steroid. In respiratory medicine there is 
evidence that biphosphonates maintain BMD in asthmatics 
on high dose inhaled treatment,188 however there are no pub-
lished data on the effectiveness of pharmacological treatment 
on COPD alone.
Non pharmacological interventions are also available. 
There is evidence that increasing skeletal muscle with 
pulmonary rehabilitation improves BMD compared to 
control, as does smoking cessation.189
Systemic inflammation in COPD results in several 
conditions which have an impact on health as described 
above. Low mood is a further consequence of COPD, 
although this is unlikely to be due to inflammation. The 
benefits of identification and management of mental health 
associated with COPD is discussed below.
Depression and anxiety in COPD
There is an increased incidence of anxiety in COPD, 
a diagnosis of generalized anxiety disorder is seen in between 
10% and 16% of subjects with compared to 4%–5% in 
the general population.190 Generalized anxiety disorder in 
COPD is associated with impaired quality of life.191 Despite 
evidence of a high prevalence of anxiety in COPD, there is 
limited evidence of benefit from therapy.190 A case report 
of 7 patients reported improved anxiety and dyspnea after 
management with the antidepressant setraline192 but there 
does not appear to be any large studies of treatment for this 
condition. Along with anxiety there appears to be a high 
incidence of depression in COPD.International Journal of COPD 2009:4 330
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Kunik et al screened 204 patients with COPD using a 
well established tool for evaluation of mental disorders. 
Thirty-nine percent were diagnosed with depression and 
26% with both depression and an anxiety disorder. Only 
31% of those subjects diagnosed with either depression or 
anxiety were receiving treatment.193 As with anxiety there 
are little significant study data on the impact of treatment of 
depression in COPD.15
Conclusion
Identifying the phenotype of COPD has become a hot topic 
in recent literature.194–197 The purpose of this review has been 
to discuss treatment of various aspects of COPD, including 
the pathological processes involved, clinical phenotypes and 
systemic manifestations. It is apparent that there is significant 
variation in many of these aspects in the COPD population. 
Furthermore, many of these have significant impact on 
morbidity and mortality. Targeting COPD treatment to 
the individual and actively identifying and managing the 
inflammatory process involved along with pulmonary and 
systemic manifestations present in that patient may help to 
reduce this impact. However, as yet, there is limited evidence 
for benefit in this approach and further study of targeting 
phenotypes is required.
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